Experts discuss emerging role of TROP2-directed ADCs in EGFR-mutated lung cancer
read at onclive ↗Neutral
The segment, part of a series on EGFR‑mutated non‑small cell lung cancer, featured Dr. Jacob Sands together with Drs. Heather Wakelee and Alissa Cooper.
They explained that TROP2‑directed antibody‑drug conjugates are designed to bind the TROP2 antigen on tumor cells and deliver a cytotoxic payload, aiming for selective tumor cell killing.
The panel highlighted the potential of these agents to complement existing therapies and discussed considerations for integrating them into treatment sequencing.
source
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs”
read at onclive ↗1,752 words · retrieved May 12
comments(0)
5-min edit window · permanent after that